Prostate cancer prevention: Strategies for agent development

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 242-251

  Parnes, Howard L ^a   House, Margaret G ^a   Tangrea, Joseph A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarker; carcinogenesis; chemoprevention; prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CASPASE 3; CATECHIN; DIINDOLYLMETHANE; DUTASTERIDE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FINASTERIDE; GENISTEIN; INDOLE DERIVATIVE; ISOFLAVONE DERIVATIVE; KI 67 ANTIGEN; LYCOPENE; OMEGA 3 FATTY ACID; PHENOL DERIVATIVE; PLACEBO; POLYPHENOL E; PROSTATE SPECIFIC ANTIGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SELENOMETHIONINE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; COHORT ANALYSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HEALTH PROGRAM; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84876287958     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835fc8d4     Document Type: Review

References (46)

1. Schulman CC, Zlotta AR, Denis L, et al. Prevention of prostate cancer. Scand J Urol Nephrol Suppl 2000; 205:50-614.
2. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98:529-534.
3. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21:525-530.
4. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002; 62:5119-5125.
5. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428.
7. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993; 7:139-146.
8. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002; 2:537-543.
9. Parnes HL, House MG, Kagan J, et al. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. J Urol 2004; 171:S68-S74.
10. Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001; 58:91-93.
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155:1985-1992.
12. Nguyen MM, Ahmann FR, Nagle RB, et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012; 5:290-298.
13. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178:S14-S19.
14. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178:2359-2364.
15. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126-131.
16. Singer EA, Kaushal A, Turkbey B, et al. Active surveillance for prostate cancer: past, present and future. Curr Opin Oncol 2012; 24:243-250.
17. Chan JM, Weinberg V, Magbanua MJ, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 2011; 22:141-150.
18. Kumar NB, Krischer JP, Allen K, et al. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007; 59: 163-168.
19. Stratton MS, Algotar AM, Ranger-Moore J, et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 2010; 3:1035-1043.
20. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001; 25:1079-1085.
21. Marshall JR, Tangen CM, Sakr WA, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 2011; 4:1761-1769.
22. Algotar AM, Stratton MS, Ahmann FR, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 2013; 73:328-335.
23. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
24. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549-1556.
25. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37:367-380.
26. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase iso-enzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179:1235-1242.
27. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
28. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihy-drotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89:2179-2184.
29. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008; 179:147-151.
30. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172:1314-1317.
31. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-1202.
32. Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365:97-99.
33. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1375-1383.
34. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98:1128-1133.
35. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276:1957-1963.
36. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90:440-446.
37. Weight CJ, Kim SP, Karnes RJ, et al. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology 2012; 80:484.
38. Antonarakis ES, Heath EI, Walczak JR, et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009; 27:4986-4993.
39. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005; 65:3470-3478.
40. Wu Y, Chhipa RR, Zhang H, Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther 2011; 11:902-909.
41. Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006; 12:2178-2184.
42. Chan JM, Weinberg V, Magbanua MJ, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 2011; 22:141-150.
43. Stratton MS, Algotar AM, Ranger-Moore J, et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 2010; 3:1035-1043.
44. Ozten-Kandas N, Bosland MC. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants-In vivo evidence. J Carcinog 2011; 10:27.
45. Simoneau AR, Gerner EW, Phung M, et al. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 2001; 93:57-59.
46. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301:52-62.